logo
Extremely rare moment off Aussie island ends six-year search for 'cryptic' species

Extremely rare moment off Aussie island ends six-year search for 'cryptic' species

Yahoo22-05-2025

Since moving to an idyllic Aussie island six years ago, two brothers have spent countless hours observing the fascinating marine creatures that live in the surrounding water. Despite their passion and persistence, one 'rare and cryptic species' has always eluded Oliver and Lawrence Scheele — until now.
Taking advantage of the nice weather on Monday, Oliver launched his drone off Queensland's Magnetic Island to try his luck. From frolicking whales to hammerhead sharks and eagle rays leaping at sunset, Oliver told Yahoo News he 'never knows' what he's going to see but hopes for the best.
After scanning the murky bay and finding 'nothing', Oliver was about to pack up and head home when what he thought was a turtle caught his eye.
'I almost was going to leave but I thought I would hold off for a bit and see if it would come back up,' he explained. 'It came back up and I thought 'that's a weird looking dugong'.'
Despite his initial confusion, the young man quickly realised it was actually an 'extremely rare' and 'very cute' Australian snubfin dolphin. Only identified as a new species in 2005, the 'unique' creatures live in shallow inshore waters across the country's north and southern Papua New Guinea.
Oliver's footage, which experts have described as 'great', shows a pod of about seven snubfin dolphins 'in a group all hunting together', including one juvenile chasing a fish gliding on the surface. In another clip, a snubfin 'imposter' can be seen trying to blend in with two Australian humpback dolphins.
'Seeing these dolphins was a privilege as they are so rare,' Oliver told Yahoo, adding he couldn't wait to tell his brother, who had long hoped to track down a photograph of a snubfin to include in his upcoming field guide about the marine life of Magnetic Island.
'It's a very amazing sighting — that's the first time I've ever seen them, and we've been actively looking for around six years,' Lawrence, a marine biologist, told Yahoo.
'They're considered highly elusive. They originally had a habitat just outside the Ross River mouth, but since that port development and the port expansion, they've moved. So ever since that happened, reportings have been less and less.'
Lawrence said the species, likened to a 'skinny dugong', was one of the final pieces of the puzzle for his book, which will soon be sent off to publishing.
'I didn't have a photo. I've never seen them before, and people I reached out to have also never seen them or don't have a photo because of their elusive nature. So it was just like divine timing finding them that morning,' he explained.
'Habitat destruction loss and degradation is really affecting their population so to see a relatively large pod of them socialising and hunting on Magnetic Island is just really special.'
🏝️ Incredible encounter of rare shark filmed near Aussie island: 'Amazing'
🦈 Locals in awe as rarely-seen creature washes up on remote beach
🌊 Incredible footage of special creature 'very rarely seen in Australia'
Australian snubfin dolphins are listed as vulnerable globally and in Queensland, with the Townsville and Cleveland Bay region home to one of the state's largest known populations, Simon Miller from the Australian Marine Conservation Society (AMCS) told Yahoo.
'But these are still small and fragmented, with limited connectivity to other populations,' he said. 'They tend to be quite a shy species that live in small populations and are typically found in shallow, turbid waters making sightings rare.'
Two of the snubfins filmed by Oliver appeared to have injuries on their tails and backs, which he believed may have been caused by boat strikes. The biggest threats to the species are bycatch in commercial gillnet fisheries, habitat degradation and climate change, according to Miller.
'Snubfin dolphins are slow to reproduce and so the loss of even small numbers of individuals can set a population back decades,' he said, adding the Queensland government's decision to phase out gillnet fishing in the Great Barrier Reef by mid-2027 is 'crucial to provide increased protection for this iconic threatened species'.
Improving the condition of inshore habitats is also vital, he said. 'Restoring degraded wetlands reduces the amount of pollutants entering the ocean which can then accumulate in species like snubfin dolphins and impact their long-term health.'
Do you have a story tip? Email: newsroomau@yahoonews.com.
You can also follow us on Facebook, Instagram, TikTok, Twitter and YouTube.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia
Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia

Yahoo

time5 hours ago

  • Yahoo

Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia

BOSTON & SYDNEY, June 09, 2025--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced the introduction of a Management Liability Insurance Policy tailored expressly for Life Science, BioTech and Pharmaceutical (LBP) companies in Australia. "The new LBP Management Liability Policy reflects our commitment to Australia's thriving life sciences community and our deep understanding of the challenges start-ups face at every stage of their journey," said Jessica Jefferies, Underwriting Manager, National Brokers, Executive & Professional Lines, BHSI Australia. "Life Sciences is one of the most promising industries in Australia and we are thrilled to be able to provide an innovative solution to support the industry". BHSI's new LBP Management Liability Insurance Policy is specifically for the R&D ecosystem – all stakeholders in Australia's diverse and energetic life sciences sector. The new product offers enhanced cover tailored for life sciences companies, with coverage not found in standard Management Liability policies. BHSI's solution will extend cover and ensure Directors, Officers, Scientific and Medical Advisory Boards all get the benefit of cover as they develop cutting-edge solutions globally. With an understanding of the funding requirements, the product provides two key elements of protection, extending cover for private capital raisings, and not excluding cover in the event of the Company's insolvency. With many Australian life sciences companies looking abroad for clinical development, BHSI's offering has the ability to extend protection to U.S. exposures, recognising the frequent pursuit of FDA approvals by Australian firms. The new solution expands BHSI's existing Management Liability policy wording for private companies and not-for-profits. BHSI is a leading market for Directors and Officers Liability insurance for ASX-listed life sciences companies in Australia. This launch extends that expertise and forms part of BHSI's strategy to provide tailored support for biotech and pharmaceutical customers from start-up to scale. To learn more, contact Berkshire Hathaway Specialty Insurance Company (incorporated in Nebraska, USA) ABN 84 600 643 034, AFS Licence No. 466713 ( provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident & health, medical stop loss, homeowners, and multinational insurance. The actual and final terms of coverage for all product lines may vary. Berkshire Hathaway Specialty Insurance Company holds financial strength ratings of A++ from AM Best and AA+ from Standard & Poor's. Based in Boston, Berkshire Hathaway Specialty Insurance has offices in Atlanta, Boston, Chicago, Columbia, Dallas, Houston, Indianapolis, Irvine, Los Angeles, New York, Plymouth Meeting, San Francisco, San Ramon, Seattle, Stevens Point, Adelaide, Auckland, Barcelona, Brisbane, Brussels, Calgary, Cologne, Dubai, Dublin, Frankfurt, Hamburg, Hong Kong, Kuala Lumpur, London, Lyon, Macau, Madrid, Manchester, Melbourne, Milan, Munich, Paris, Perth, Singapore, Stockholm, Sydney, Toronto, and Zurich. View source version on Contacts MEDIA CONTACTJoAnn Lee / +1 617.936.2937

Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia
Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia

Business Wire

time5 hours ago

  • Business Wire

Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia

BOSTON & SYDNEY--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced the introduction of a Management Liability Insurance Policy tailored expressly for Life Science, BioTech and Pharmaceutical (LBP) companies in Australia. 'The new LBP Management Liability Policy reflects our commitment to Australia's thriving life sciences community and our deep understanding of the challenges start-ups face at every stage of their journey,' said Jessica Jefferies, Underwriting Manager, National Brokers, Executive & Professional Lines, BHSI Australia. 'Life Sciences is one of the most promising industries in Australia and we are thrilled to be able to provide an innovative solution to support the industry'. BHSI's new LBP Management Liability Insurance Policy is specifically for the R&D ecosystem – all stakeholders in Australia's diverse and energetic life sciences sector. The new product offers enhanced cover tailored for life sciences companies, with coverage not found in standard Management Liability policies. BHSI's solution will extend cover and ensure Directors, Officers, Scientific and Medical Advisory Boards all get the benefit of cover as they develop cutting-edge solutions globally. With an understanding of the funding requirements, the product provides two key elements of protection, extending cover for private capital raisings, and not excluding cover in the event of the Company's insolvency. With many Australian life sciences companies looking abroad for clinical development, BHSI's offering has the ability to extend protection to U.S. exposures, recognising the frequent pursuit of FDA approvals by Australian firms. The new solution expands BHSI's existing Management Liability policy wording for private companies and not-for-profits. BHSI is a leading market for Directors and Officers Liability insurance for ASX-listed life sciences companies in Australia. This launch extends that expertise and forms part of BHSI's strategy to provide tailored support for biotech and pharmaceutical customers from start-up to scale. To learn more, contact Berkshire Hathaway Specialty Insurance Company (incorporated in Nebraska, USA) ABN 84 600 643 034, AFS Licence No. 466713 ( provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident & health, medical stop loss, homeowners, and multinational insurance. The actual and final terms of coverage for all product lines may vary. Berkshire Hathaway Specialty Insurance Company holds financial strength ratings of A++ from AM Best and AA+ from Standard & Poor's. Based in Boston, Berkshire Hathaway Specialty Insurance has offices in Atlanta, Boston, Chicago, Columbia, Dallas, Houston, Indianapolis, Irvine, Los Angeles, New York, Plymouth Meeting, San Francisco, San Ramon, Seattle, Stevens Point, Adelaide, Auckland, Barcelona, Brisbane, Brussels, Calgary, Cologne, Dubai, Dublin, Frankfurt, Hamburg, Hong Kong, Kuala Lumpur, London, Lyon, Macau, Madrid, Manchester, Melbourne, Milan, Munich, Paris, Perth, Singapore, Stockholm, Sydney, Toronto, and Zurich.

Used in COVID shots, mRNA may help rid the body of HIV
Used in COVID shots, mRNA may help rid the body of HIV

Chicago Tribune

time5 hours ago

  • Chicago Tribune

Used in COVID shots, mRNA may help rid the body of HIV

The technology that powered COVID vaccines may also lead scientists to a cure for HIV. Using mRNA, Australian researchers said they were able to trick the virus to come out of hiding, a crucial step in ridding the body of it entirely. The research, published last week in Nature Communications, is still preliminary and so far has been shown to be successful only in a lab. But it suggests that mRNA has potential far beyond its use in vaccines as a means to deliver therapies against stubborn adversaries. Short for messenger RNA, mRNA is a set of instructions for a gene. In the case of COVID vaccines, the instructions were for a piece of the coronavirus. In the new study, they are for molecules key to targeting HIV. Dr. Sharon Lewin, director of the Doherty Institute at the University of Melbourne, who led the study, called mRNA a 'miraculous' tool 'to deliver things that you want into places that were not possible before.' Vaccines deploying mRNA instruct the body to produce a fragment of the virus, which then sets off the body's immune response. In the United States, the shots were initially hailed for turning back the pandemic, then viewed by some with suspicion and fear. Some officials, including Health Secretary Robert F. Kennedy Jr., have falsely said that they are highly dangerous and even deadly. Last week, the Department of Health and Human Services sought to limit the vaccine's availability to pregnant women, children and healthy younger adults. The administration also canceled a nearly $600 million contract with the drugmaker Moderna to develop an mRNA shot for humans against bird flu. 'The fear right now is not rational,' Lewin said, adding that 'mRNA vaccines have been given to millions of people around the world, so we have a very good understanding of their risks.' The new study describes the use of mRNA as a tool to flush HIV out of its hiding places. Other uses could involve providing proteins missing from those with certain diseases or correcting genetic errors. Frauke Muecksch, a virologist at Heidelberg University in Germany who was not involved in the work, called mRNA a 'promising, absolutely powerful technology.' Although most people may have only heard of mRNA's use in science during the pandemic, scientists have been working with it for more than 20 years, she said. 'I think it's not just therapeutically very powerful, but also for basic science, for research, it opens up a lot of avenues,' she added. Potent antiretroviral drugs can now control HIV, suppressing it to undetectable levels. Still, minute amounts of the virus lie dormant in so-called reservoirs, waiting for an opportunity to resurge. A cure for HIV would involve ferreting out all of this virus and destroying it, a strategy that has been called 'shock and kill.' A significant hurdle is that the virus lies dormant in a particular type of immune cell, called a resting CD4 cell. Because these cells are inactive, they tend to be unresponsive to drugs. The few drugs scientists have previously used to rouse the virus in these cells were not specific to HIV and had unwanted side effects. 'It's fair to say the field's been a little bit stuck,' said Brad Jones, a viral immunologist at Weill Cornell Medicine who was not involved in the latest research. In 2022, Jones and his colleagues found that the immune boost from the mRNA vaccines awakened latent HIV in people living with the virus. (Other research has shown that mRNA vaccines also activated dormant viruses including Epstein Barr.) 'You get just a little bit of a gentle nudge with some of these vaccines, and it's enough to coax some of these latent viruses out so they can be killed,' Jones said. Lewin and her colleagues had for years experimented with other ways to activate HIV but had no luck in resting cells. Seeing the success of the COVID vaccines, which used lipid nanoparticles — tiny spheres of fat — containing mRNA, her team tested similar particles. They used the particles to deliver two different sets of molecules: Tat, which is adept at switching HIV on, and CRISPR, a tool that can 'edit' genes. The researchers showed that in resting immune cells from people living with HIV, the approach coaxed the virus out of dormancy. 'It's very, very hard to deal with these cells, so I think this really targeting the right population of cells is what makes this paper special,' Muecksch said. It's unclear whether the new approach can successfully awaken all of the dormant HIV in the body, and what side effects it might produce. Lewin said that 'mRNA will almost certainly have some adverse effects, as every drug does, but we will investigate that systematically, as we do for any new drug.' In this case, she said, side effects may be more acceptable to people living with HIV than having to take medications for the rest of their lives. The researchers plan to test the method in HIV-infected animals next, before moving into clinical trials. This article originally appeared in The New York Times.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store